GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
Source | Last Updated |
---|---|
GlycoNAVI Proteins | November 21, 2024 |
PDB ID | UniProt ID | Title ▼ | Descriptor |
---|---|---|---|
4EIS | Q7SA19 | Structural basis for substrate targeting and catalysis by fungal polysaccharide monooxygenases (PMO-3) | polysaccharide monooxygenase-3 |
4EIR | Q1K8B6 | Structural basis for substrate targeting and catalysis by fungal polysaccharide monooxygenases (PMO-2) | |
3A7Q | Q60841 | Structural basis for specific recognition of reelin by its receptors | |
3A7Q | Q14114 | Structural basis for specific recognition of reelin by its receptors | |
2E33 | Q80UW2 | Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase | |
2E33 | P61823 | Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase | |
6C0B | M4NKV9 | Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B | Toxin B, Frizzled-2 |
6C0B | Q14332 | Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B | Toxin B, Frizzled-2 |
7CAB | P0DTC2 | Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | SARS-CoV-2 Spike glycoprotein |
5NUP | D6QLY0 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
5NUP | A0A0W8AQT6 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
5NUR | P02931 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
5NUR | A0A0W8AQT6 | Structural basis for maintenance of bacterial outer membrane lipid asymmetry | |
3ZS5 | Q16539 | Structural basis for kinase selectivity of three clinical p38alpha inhibitors | |
4ZG6 | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | |
4ZG7 | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E.C.3.1.4.39) |
4ZG9 | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E.C.3.1.4.39) |
4ZGA | Q13822 | Structural basis for inhibition of human autotaxin by four novel compounds | Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E.C.3.1.4.39) |
3RKI | P03420 | Structural basis for immunization with post-fusion RSV F to elicit high neutralizing antibody titers | |
6OHW | Q696P8 | Structural basis for human coronavirus attachment to sialic acid receptors. Apo-HCoV-OC43 S | Spike surface glycoprotein |
6NZK | Q696P8 | Structural basis for human coronavirus attachment to sialic acid receptors | Spike surface glycoprotein |
7N1Q | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7N1T | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7N1U | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7N1V | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7N1W | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7N1X | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7N1Y | P0DTC2 | Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | |
7C8K | E2DHI3 | Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to bat ACE2 | Angiotensin-converting enzyme (E.C.3.4.-.-) |
5VK2 | P08669 | Structural basis for antibody-mediated neutralization of Lassa virus | |
5VK2 | 5VK2 | Structural basis for antibody-mediated neutralization of Lassa virus | |
1TYE | P08514 | Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen | |
1TYE | P05106 | Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen | |
1UXQ | O57693 | Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax | |
1UXR | O57693 | Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax | |
1UXT | O57693 | Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax | |
7KFY | P0DTC2 | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) | |
7KFY | 7KFY | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) | |
7KFX | P0DTC2 | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) | |
7KFX | 7KFX | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) | |
7KFW | P0DTC2 | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) | |
7KFW | 7KFW | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) | |
7KFV | P0DTC2 | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) | |
7KFV | 7KFV | Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) | |
2V5M | Q9NBA1 | Structural basis for Dscam isoform specificity | DSCAM |
2V5R | Q9NBA1 | Structural basis for Dscam isoform specificity | |
2V5R | 2V5R | Structural basis for Dscam isoform specificity | |
2V5R | Q9NBA1 | Structural basis for Dscam isoform specificity | |
2V5R | 2V5R | Structural basis for Dscam isoform specificity | |
2V5S | Q9NBA1 | Structural basis for Dscam isoform specificity |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024